Overview

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
Ampicillin
Clavulanic Acid
Clavulanic Acids
Minocycline
Sulbactam
Sultamicillin
Tigecycline
Criteria
Inclusion Criteria:

- Clinical diagnosis of complicated skin or skin structure infection

- Male or female, 18 years or older

- Need for intravenous treatment for 4 to 14 days

Exclusion Criteria:

- Skin infection that can be treated by surgery & wound care alone

- Diabetic foot ulcers or bedsores where the infection is present longer than 1 week

- Poor circulation such that amputation of the infected site is likely within a month
Other exclusions apply